Terminal / Weight Loss

Liraglutide

Approved

aka Saxenda, Victoza

The original once-daily GLP-1. Semaglutide's older, shorter-acting predecessor.

Mechanism

A GLP-1 agonist you inject daily instead of weekly. Same idea as semaglutide, slows the stomach and raises satiety, just an older and shorter-acting molecule. It was the first GLP-1 to get the green light for chronic weight management.

Regulatory & Safety Status

Approved: Victoza for diabetes, Saxenda for obesity. Prescription drug, mostly superseded by the weekly options now.

Research

2026The Annals of pharmacotherapy

Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment

2026Diabetologia

Unimolecular GLP-1/APJ receptor co-agonism improves metabolism and dyslipidaemia as well as normalising hepatic triglyceride and aminotransferase elevation in high-fat-fed mice

2026Cardiovascular drugs and therapy

Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue

2026Childhood obesity (Print)

Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists

2024PubMed

Latest liraglutide research

Related Compounds

Weight Loss

Semaglutide

Approved

Approved GLP-1 agonist. The drug that kicked off the whole weight-loss gold rush.

Weight Loss

Tirzepatide

Approved

Approved dual agonist (GLP-1 and GIP). Currently the strongest thing you can get with a prescription.